Latest Channel 4 News:
Online auctioneer set for Xmas rush
Goldsmith 'expressed doubt' on Iraq
Hacker 'wants prosecution in UK'
Banks back Hershey bid for Cadbury
Checks on parents at school events

Bullfrog could help superbug fight

Updated on 30 April 2007

Source PA News

American bullfrogs could hold the key to eliminating the MRSA superbug from hospital wards, scientists said.

Researchers at St Andrews University have developed a novel treatment which kills the infection.

One of its key ingredients is ranalexin, a protein secreted by the Rana species of bullfrogs.

When scientists combined it with the enzyme lysostaphin they found had a "potent and significant" inhibitory effect on MRSA.

Microbiologist Dr Peter Coote, who led the study, said: "Our finding represents a potentially novel way to combat MRSA via surface treatment or impregnation of wound dressings.

"Together the ranalexin and lysostaphin are very, very potent as any resistance has to overcome two hurdles.

"They kill the organism extremely quickly and effectively."

The 18-month study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC).

Dr Coote's team have applied for a further grant which will allow them to continue their research.

They are also in touch with pharmaceutical companies to see if the treatment could be marketed commercially in the future.

These news feeds are provided by an independent third party and Channel 4 is not responsible or liable to you for the same.

Send this article by email


Watch the Latest Channel 4 News

Watch Channel 4 News when you want

Latest Health news

7-day catch-up

Watch Channel 4 News when you want to, from the last week.

Sign up to Snowmail

The day's news from Jon Snow and the team direct to your inbox.

Week in pictures

credit: Reuters

A selection of the best pictures from around the world.

Most watched

Most watched

Find out what's getting people clicking online this week.




Channel 4 © 2009. Channel 4 is not responsible for the content of external websites.